Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (221)	12/12/2000 11:15:00 AM
From: tuck	Read Replies (2) \| Respond to of 1784

Wilder, Thanks for the pointer. As mentioned in other posts, Trickle doesn't travel well. The wheels fall off the the SI quote server when asked to cough up a foreign quote. This is quite frustrating, as several companies trickle is interested in suffer from the problem. And who knows what the portfolio interface might do when I try to sell something. I believe that's what messed up Rick's original trickle portfolio. The ultimate solution is to develop a spreadsheet a la VD's model portfolio, unless SI fixes the problem first. It'll be a while before I get to that point. But keep the pointers coming, I will keep the foreign stuff in mind. Cheers, Tuck

To: keokalani'nui who wrote (221)	3/7/2001 8:09:10 AM
From: nigel bates	Respond to of 1784

March 7 /PRNewswire/ -- EVOTEC BioSystems AG (EVOTEC OAI) (Neuer Markt: EVT) today announced that EVOscreen® Mark II, the world's first fully-operational, automated, miniaturized system accurate to one microliter, designed for ultra-high throughput screening (uHTS), has been successfully tested and accepted by Glaxo SmithKline (GSK) in Harlow, England. Consequently, all three of EVOTEC OAI's current technology development partners are now equipped with EVOscreen® technology on site. Since May 2000 EVOscreen® Mark II, designed for GSK, has been undergoing testing by GSK scientists in Hamburg. The results of their experiments have demonstrated the robustness of the screening system. In addition three biological assays were successfully performed in ultra high throughput format using different read out parameters. EVOscreen® Mark II was shipped for installation at GSK in November 2000. The site acceptance tests significantly exceeded the pre-defined specifications and the timelines for the project were fully met. ``The successful delivery of the EVOscreen® Mark II instrument to GSK demonstrates not only the excellence and robustness of the technology developed by EVOTEC, but also the value of the collaboration between scientists of both companies to realize the development of a superior instrument suitable for advancing high-throughput screening to a new level of performance'', commented Thomas Meek, Head of Screening Sciences at Glaxo SmithKline. EVOTEC OAI is very pleased with the close cooperation and scientific team work between the two companies on this program. EVOTEC OAI has provided an intensive training program and scientists at GSK are now familiar with operating the complete system. Feedback from GSK along the way has also helped to improve the performance of the Mark II. In conjunction with GSK, EVOTEC OAI is currently developing the next generation of its ultra-high-throughput screening platform, EVOscreen® Mark III. It integrates further technological advances, particularly in the field of cellular assays. In addition, the flexible system architecture allows the use of additional devices, integrated in part with the support of GSK software developers. The Mark III project is currently on schedule and it is anticipated that the system will be delivered to GSK by the end of 2001. EVOscreen® is the world's first fully-operational, automated miniaturized system, accurate to one microliter, designed for ultra-high throughput screening (uHTS). With this technology EVOTEC OAI has added a new dimension of efficiency in the process of identifying novel potential drug candidates. EVOscreen®'s potential is based on the combination of miniaturization, automation and EVOTEC OAI's proprietary single-molecule detection technology. The system has the potential for a throughput of 100,000 tests per day. In the process of analyzing minute assay volumes it generates data of high information content and delivers cost savings by significantly reducing the consumption of valuable reagents. With EVOscreen®, EVOTEC OAI has secured a leading position in the field of ultra high throughput screening (uHTS)...